This article reviews the pathophysiology of antibody-mediated rejection (AMR) with emphasis on the role of complement in allograft injury. It reviews the required features for a definitive diagnosis of AMR according to the latest Banff criteria, which incorporate recent findings delineating the complex spectrum of AMR and the diverse phenotypes seen. Clinical data on current and investigational treatments are summarized, and strategies to improve outcomes are presented. Lastly, a discussion of relevant predictive and surrogate endpoints provides a framework for future studies.
protected and nurtured in bone marrow niches, a scenario equivalent to a vaccine response from a previous exposure to allogeneic HLA molecules. 2 These LLPCs do not have a significant capacity to increase basal antibody production in response to donor HLA. Thus, AMR fol- AMR is also of significant concern in nonsensitized individuals, as de novo DSAs can develop early or late after transplantation. 2 Early appearance of de novo DSAs weeks to months after transplantation may cause acute AMR and can be severe. AMR is seen in up to 5%
of first transplants and in some cases may represent an anamnestic response from cryptic sensitization in which HLA-specific memory B cells are present but soluble antibody is not being produced or is not detectable. Late or chronic AMR may result from de novo DSA formation, incomplete elimination of DSA following an acute AMR episode, or persistence of preformed DSA after desensitization. AMR is often diagnosed late and may only manifest as an insidious rise in serum creatinine. De novo antibody formation and chronic AMR are thought to be a significant cause of premature graft failure.
The deleterious impact on graft half-life of all forms of AMR can be profound. 3 Orandi and colleagues found a 4.73-fold higher risk of graft loss in patients with AMR (95% confidence interval [CI], 1.57-14.26; P = .006). 4 In the case of deceased donor transplants in which lowlevel DSA is present, they found a somewhat attenuated AMR effect on graft loss (hazard ratio [HR] = 2.39; 95% CI, 1.10-5.19; P = .028), while in HLA-incompatible live donor transplants, the impact of AMR appeared even stronger (HR = 6.29; 95% CI, 3.81-10.39; P < .001), likely due to higher pre-desensitization antibody strength.
The best treatment for AMR is prevention. While AMR will always be a feature of the practice of allogeneic transplantation, the incidence can be greatly reduced by measures to reduce risk by avoiding strong DSA. The new kidney allocation system, which gives priority to the allocation of non-normative donor HLA genotypes to highly sensitized patients, is an example of how policy can influence transplant outcomes and equity. Kidney paired donation, combining paired donation with desensitization, and acceptable mismatch strategies all are ways of reducing the risk of AMR and its consequences.
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| PATHOPHYSIOLOGY OF COMPLEMENT-MEDIATED AMR
There has been an increasing awareness of the important role of complement in the pathophysiology of acute AMR. The link between complement and AMR was confirmed when the complement split product
C4d was demonstrated in transplant biopsies. 9 Corroboration by additional investigations led to development of consensus diagnostic criteria for acute and chronic AMR in renal transplantation that included detection of DSA in the serum and C4d deposition in the allograft. 10, 11 The major mechanism involved in antibody-mediated kidney injury is activation of the classical complement pathway by the binding of DSA to HLA and subsequent binding of the C1 complex, which ultimately leads to formation of the membrane attack complex (C5b-C9) and results in direct injury to the allograft ( Figure 1 ). 12 The extent of complement activation by immune complexes is influenced by a variety of local and systemic factors, including antibody strength, 13, 14 antibody isotype, epitope density, and the local concentration of complement regulatory proteins. 15 Immunoglobulin G (IgG)3 and IgG1 DSAs have strong capability to bind C1q and activate the classical pathway, whereas IgG2 and IgG4 DSAs have weaker C1-fixing properties. 15, 16 F I G U R E 1 The role of the classical complement pathway in acute AMR in sensitized renal transplant recipients. Following binding of DSA to the allograft vascular endothelium, the C1 complex activates the serine esterases C1s and C1r, resulting in the cleavage of C4, deposition of C4d, and the assembly of the classical pathway C3 convertase. C3 convertase cleaves C3 into C3a, a potent pro-inflammatory mediator, and C3b, which propagates the complement cascade and leads to the formation of the pro-inflammatory mediator C5a and the lytic membrane attack complex (C5b-C9 The complex spectrum of AMR in renal allografts is only recently becoming better defined. AMR has multiple phenotypes related to the mechanism of DSA production and injury (preformed DSA vs de novo DSA), the strength of antibody reactivity, and the timing of rejection.
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Updated 2013 Banff criteria for AMR now take into account recent data supporting the recognition of subclinical AMR as part of the AMR spectrum, the existence of C4d-negative AMR, and antibodymediated vascular rejection (AMVR) characterized by intimal arteritis (Table 1) . 19 Although AMR phenotypes are now organized as acute AMR, subclinical AMR, and chronic AMR, it is recognized that AMR is a continuous process with varying degrees of activity and damage.
Further refinement of the Banff criteria will help determine whether this continuum corresponds to distinct pathophysiology, molecular signatures, involvement of complement-dependent and independent processes, and responses to precision therapies, which were topics of discussion during the 13th meeting of the Banff Conference on Allograft Pathology. 20 At present, there is still significant ambiguity in the Banff criteria in terms of the classification and behavior of the different forms of AMR. The Banff classifications are primarily focused on the presence or absence of detectable complement activation (type 1 vs type 2).
The timing of the AMR relative to the transplant and the presence of presensitization are important factors in determining phenotype and response to therapy. Patients with preformed DSA, many of whom undergo desensitization protocols, are at greatest risk for early acute AMR, primarily due to anamnestic responses. However, these patients can develop acute AMR at any point in time after transplantation.
Early acute AMR can be severe and result in graft loss, but it is also potentially responsive to treatment and, when it is, often results in the disappearance of DSA. 21 Late acute AMR (more than 3 months posttransplant) can be a mixed cellular and antibody rejection, and it is often recalcitrant to standard of care (SOC) therapy, as is chronic AMR and, in some cases, subclinical AMR, which are commonly associated with transplant glomerulopathy and reduced graft half-life.
This review will attempt to make these distinctions when describing histologic phenotypes and efficacy of available treatments.
| Complement activation and AMR
Findings from a number of investigations have demonstrated that
DSAs may cause graft injury independent of C4d deposition. high endothelial-associated transcript (ENDAT) expression was an indicator of active antibody-mediated allograft damage and was associated with a significantly increased rate of graft loss, even in the absence of C4d. 24 The findings of Loupy et al support the existence of C4d-negative AMR that, although less severe than C4d-positive AMR, is still associated with the development of chronic allograft changes and reduced allograft half-life. 25 Various techniques for detecting complement activation by allo-HLA have been described, including immunofluorescence, immunoperoxidase, and C1q binding. 28, 29 All are adept at demonstrating or predicting C4d-positive AMR. The classic diagnostic pattern of C4d deposition is diffuse staining in the ptc. 30 In a large clinical series, Kikić et al found less commonly recognized C4d deposition patterns, including focal linear C4d in ptc, endothelial C4d in glomeruli, or arteriolar C4d, which correlated with glomerulitis, presensitization, and poor graft survival. 31 These diverse techniques and recognition of novel 
| TREATMENT OF AMR
The current strategy for treating AMR is use of a combination of modalities to address multiple pathophysiologic pathways. Treatment regimens of plasmapheresis 34 or immunoadsorption 35 followed by low-dose intravenous immunoglobulin (IVIg; 100 mg/kg) or high-dose IVIg (2 g/kg) with or without steroids have become the SOC based on a preponderance of supporting data rather than randomized controlled trials. 36, 37 High-dose IVIg is often used in combination with anti-CD20
(rituximab) despite mixed evidence of its added benefit (see the section that follows on anti-CD20). Kidney Disease: Improving Global
Outcomes clinical practice guidelines recommend the use of these 2 treatment regimens, and most insurers will reimburse for therapy involving this combination of modalities. 36, 38 A recent clinical practice survey found that AMR treatments vary widely, with most centers using a combination of plasmapheresis and IVIg, with a number also incorporating rituximab. 39 Plasmapheresis and immunoadsorption directly remove IgG from the serum in a fairly predictable fashion but are inefficient inasmuch as IgG is removed only from the vascular space and then must reequilibrate with the interstitium before further antibody removal is optimal, a process that takes about 48 hours. There is evidence that low-dose IVIg dampens endogenous antibody rebound after depletion with plasmapheresis. IVIg also serves to restore antimicrobial immunoglobulins removed during plasmapheresis. Few randomized controlled trials are available to assess the effectiveness of plasmapheresis and immunoadsorption in treating AMR. A small but well-designed study by Böhmig et al using immunoadsorption vs conventional immunosuppression for severe C4d-positive AMR was terminated early due to the high rate of graft loss in the control arm. 35 Another early randomized controlled trial comparing plasmapheresis with standard immunosuppression for early "vascular rejection" (not biopsy-proven AMR)
showed no difference in graft survival. 40 Other randomized controlled studies (summarized in Roberts et al) of low or uncertain quality were inconsistent in showing a benefit of plasmapheresis for the treatment of AMR. 36 Investigations in the early 1990s suggested the therapeutic potential of IVIg was due primarily to anti-idiotypic interactions with HLA antibodies. 36, 41 At high doses, IVIg exhibits immunomodulatory effects on T and B cells, including induction of B cell apoptosis and modulation of B cell signaling. 42 In a multicenter, placebo-controlled, randomized trial, IVIg alone was shown to increase transplant rates for highly sensitized patients and resulted in a modest reduction in panel reactive antibodies. 43 Other studies have suggested that highdose IVIg alone is only effective against low-level antibodies. 44, 45 In an uncontrolled study, the group at Cedars-Sinai Medical Center (in Los Angeles, California, USA) found improved graft survival rates when
anti-CD20 was combined with high-dose IVIg. 46 High DSA levels may exceed the therapeutic capacity of both plasmapheresis and IVIg, and tissue destruction due to complement fixation will occur. Anti-CD20, 
| Anti-CD20
Rituximab, a chimeric monoclonal IgG antibody directed against the CD20 antigen expressed on the surface of pre-B and mature B cells, causes B cell lysis via both complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. 47 It is approved for use in several B cell lymphomas and leukemias as well as in rheumatoid arthritis. Rituximab appears to be ineffective for the treatment of AMR. Antibody-secreting plasma cells do not express CD20 and would not be expected to have any response to anti-CD20. 48 One systematic review and meta-analysis of 10 small retrospective or nonrandomized trials evaluating use of rituximab in AMR suggested that use of this agent is associated with improved graft outcome; however, the favorable effect was driven by 2 larger studies included in the analysis. 49 A systematic review of 21 studies (2 randomized controlled trials and 19 retrospective cohort studies) did not support the use of rituximab in desensitization in highly sensitized recipients. 50 The first controlled trial of rituximab, which was not well designed,
showed that adding rituximab to plasmapheresis and IVIg provided improved graft outcome over that seen with IVIg alone. It is likely that the benefit could be attributed to plasmapheresis and not to the rituximab. 51 A study by Oblak et al failed to show any benefit of adding rituximab to SOC treatment for AMR.
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A small phase III, multicenter, double-blind study evaluating rituximab as an addition to plasma exchange, IVIg, and corticosteroids for treatment of acute AMR (n = 38) found no additional benefit of rituximab on a composite primary endpoint of graft loss and renal function at day 12, compared with placebo (52.6% vs 57.9%, respectively; P = .744). 53 At 1 year, no deaths occurred, but 1 graft loss was seen in each group. The authors conclude that the study was underpowered and that important differences between groups may have been missed, but there did not appear to be a benefit to using rituximab for established AMR.
There is some evidence that rituximab could be effective in 
| Proteasome inhibitors
Bortezomib, which is approved for use in multiple myeloma and mantle cell lymphoma, is a proteasome inhibitor that disrupts the normal intracellular protein degradation process. 57 Plasma cells are sensitive to proteasome inhibition due to their continuous production of immunoglobulins, and in 1 study bortezomib has been shown to induce plasma cell apoptosis and block anti-HLA antibody production. showed that renal function at 9 months was better in the bortezomib group compared with the historical rituximab group; in addition, graft survival at 18 months was higher (60% vs 11%, P = .0171). 62 Other studies have shown no improvement in glomerular filtration rate after bortezomib when used as add-on therapy with plasmapheresis and IVIg for chronic AMR. 63 The finding that bortezomib has little effect on HLA class II antibody production may explain its lack of efficacy for late or chronic AMR. 64 
| IL-6R blockade
A humanized monoclonal antibody against the IL-6R (tocilizumab) has been used in phase I/II studies for the treatment of chronic active AMR unresponsive to SOC therapy and with high-dose IVIg for patients who are difficult to desensitize. 65 In 1 study of 75 patients with chronic active AMR with or without transplant glomerulopathy, 37
patients who had failed high-dose IVIg, rituximab, and plasmapheresis received monthly doses of tocilizumab for 6 to 18 months and were found to have good outcomes when compared with published results.
Anti-IL-6R therapy has also been used in combination with high-dose IVIg and anti-CD20 for patients who failed SOC desensitization, and it appeared well tolerated and safe. 66 There are no published randomized controlled trials showing the benefit of tocilizumab at this time.
| COMPLEMENT INHIBITOR STRATEGIES IN AMR
Since the activation of complement in the setting of high levels of DSA plays a major role in the pathogenesis of acute AMR, it makes sense that complement blockade would be an important strategy for prevention and treatment of AMR. Agents targeting C5 and C1 esterase have been evaluated in clinical trials.
| C5 inhibition
Eculizumab is a humanized monoclonal IgG antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b and blocking the generation of the terminal complement complex C5b-C9 ( Figure 1) . 67 Approved by the FDA for use in the treatment of paroxysmal nocturnal hemoglobinuria and primary atypical hemolytic uremic syndrome (aHUS), eculizumab has been used off-label in the kidney transplant setting for the prevention and treatment of aHUS, antiphospholipid syndrome, and catastrophic antiphospholipid syndrome.
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The first case report on the use of eculizumab to treat severe AMR demonstrated that administration of the drug in combination with plasmapheresis and low-dose IVIg led to a marked decrease in C5b-C9 complex deposition in the kidney and a reversal of the AMR episode. 72 In a single-arm phase I/II trial conducted at the Mayo Clinic that included 26 highly sensitized recipients of living-donor renal transplants (NCT006707), eculizumab in combination with plasmapheresis resulted in a statistically significant reduction in AMR in the first 3 months compared with 51 historic controls receiving plasmapheresis alone (7.7% vs 41.2%, respectively; P = .0031). 73 In this study, eculizumab was dosed at 1200 mg immediately prior to transplantation, 600 mg on postoperative Day 1, and then 900 mg weekly thereafter for 4 weeks; patients with persistently high DSA continued treatment (1200 mg at week 5 and every 2 weeks afterward) until the B flow crossmatch channel shift fell below 200. In this study, eculizumab does not appear to affect DSA levels, as the percentage of patients who developed high levels of DSA posttransplantation was similar among eculizumab-treated patients and the control group. Among patients with high DSA levels and C4d+ staining, significantly fewer patients receiving eculizumab developed AMR compared with historical controls (15% vs 100%, P < .0001). However, despite the lower incidence of AMR at 3 months, the incidence of chronic AMR at 1-to 2-years posttransplant was not significantly reduced. 74 In addition, no significant differences were noted at 1 and 2 years between patients receiving eculizumab and historical controls with regard to transplant glomeru- at Weeks 5, 7, and 9) was effective in reducing the incidence of acute AMR (7.5% vs 30% seen with historical controls). 76 In a Johns Hopkins study of 24 patients who developed severe, oliguric AMR after desensitization and transplantation with a live donor kidney, Orandi et al found that a combination of splenectomy with eculizumab as an add-on therapy to plasmapheresis/low-dose IVIg and rituximab resulted in the highest graft salvage rate and protection from transplant glomerulopathy compared with splenectomy alone or eculizumab alone as an add-on therapy. 77 A potential mechanistic explanation for the success of this combined therapy is that splenectomy removes antibody-producing plasmablasts and plasma cells that traffic to the spleen from regional lymphoid tissue, 78 and eculizumab protects the endothelium from injury while plasmapheresis clears residual circulating antibody. In other words, splenectomy increases rescue rates by reducing DSA production, and eculizumab prevents transplant glomerulopathy by protecting the microvascular circulation. However, the Mayo Clinic's study suggests that eculizumab's protective effect may not be durable if strong DSA is allowed to persist for long periods of time. In the Mayo Clinic's study, DSA was not reduced or controlled after desensitization and transplantation.
In a small pilot, randomized, controlled trial by Kulkarni et al, eculizumab was compared to observation for chronic active AMR. 79 The treatment group showed a modest improvement in estimated glomerular filtration rate (eGFR) trajectory and no difference in ENDAT.
Inclusion in this study was based on the development of de novo DSA and deteriorating renal function and not on biopsy-proven chronic AMR. The primary endpoint was change in eGFR, which is not a good outcome to establish efficacy as changes in eGFR occur late after ongoing injury and are not a specific finding for chronic AMR.
Eculizumab failures have been reported in cases of C4d-negative AMR. 80 The presence of glomerular and capillary inflammation after eculizumab treatment suggests that terminal complement inhibition, which does not affect deposition of C4d or generation of the pro-inflammatory factor C3a, has limitations, especially when DSA is present and persists at high strength. AMR phenotypes, in relation to complement binding capacity 81 or IgG subclass, 16 change over time,
and thus the design of eculizumab studies in the future needs to be more refined. The complexity of AMR requires a more personalized therapy with a more precise assessment of phenotypes that are responsive to C5 inhibition. Data from additional ongoing studies will provide important information regarding use of this agent in these patient populations.
| C1 esterase inhibition
C1-INH is a serine protease inhibitor that inactivates both C1r and C1s and has multiple effects. C1-INH regulates proteases in the classical and lectin complement pathways and has major effects on regulation of the coagulation cascade as well as vascular permeability and inflammation by kinins (Figure 2) . 82 
| IdeS
Phase I/II testing (NCT02790437) has begun for a new compound called
IgG-degrading enzyme of Streptococcus pyogenes (IdeS). 89 This enzyme cleaves at a very specific amino acid sequence in the hinge region of During the period prior to the DSA rebound, they receive single doses of IVIg and rituximab. A total of 20 patients at 3 centers will be enrolled.
| HOW CAN AMR OUTCOMES BE IMPROVED?
Successful management of HLA sensitization and AMR continues to represent an important unmet need in solid organ transplantation. Recognition of the prognostic implications of subclinical AMR has been an area of increasing importance because of the association with reduced graft function. 25 Among patients with preformed antibody, 1 year after transplantation 13% of patients were found in 1 study to have subclinical TCMR, and 14% of patients were found to have subclinical AMR. Importantly, patients with subclinical AMR had the poorest graft survival at 8-years posttransplant (56%) compared with the subclinical TCMR (88%) and nonrejection (90%) groups (P < .001). 88 This study also found that subclinical TCMR could be a contributing factor to the subsequent development of de novo DSA and AMR.
The ability to assess various qualitative DSA properties, such as C1q binding, affinity strength, MFI levels in class I vs class II antibodies, IgG subclass, and preformed vs de novo antibody, has contributed greatly to our understanding of the wide spectrum of graft injury attributed to anti-HLA DSAs detected after transplantation. 16, 82, [92] [93] [94] [95] [96] [97] [98] [99] IgG subclass 3 predominates in acute AMR phenotypes, and in this situation the ability to bind C1q may be dependent only upon antibody strength. 100 Qualitative differences in C1q binding may reflect AMR phenotypes in which IgG subclass 4 is dominant. There are differences in the response to therapy of class I vs class II antibody, inasmuch as class II antibody is more difficult to eliminate with plasmapheresis, more often associated with chronic active AMR and transplant glomerulopathy, and associated with a worse prognosis.
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The potential for gene expression signature as an additional criterion for a more refined diagnosis and risk stratification of AMR is increasingly being recognized. The Alberta Transplant Applied Genomics
Centre recently developed a microarray-based "molecular microscope"
test that includes AMR-associated genes, which are mainly related to endothelial cell injury or natural killer cells or are interferon-γ inducible. 102 In 1 study, AMR scores assigned to 403 biopsies based on this test set of genes strongly predicted future graft loss, and the test was validated in a separate group of 300 biopsies in the INTERCOM study 103 to communicate this information to clinicians and obtain detailed feedback.
Finally, non-HLA antibodies (eg, anti-endothelial, anti-AT1R, and anti-MICA) can cause injury that has histologic features that recapitulate the phenotypes caused by HLA antibodies. 104 There are small series and case reports describing therapeutic success for AMR caused by non-HLA antibodies using the same interventions and drugs described in this review. There are efforts under way to use molecular techniques to identify the targets for these antibodies. 105 However, little is currently known about the nature of the majority of non-HLA antibodies, and this topic deserves a separate discussion as the field emerges.
| CLINICAL IMPLICATIONS OF SURROGATE ENDPOINTS IN AMR CLINICAL TRIALS: WHY ARE THEY NEEDED?
The current gold-standard clinical endpoint in renal transplantation is patient and graft survival measured at an appropriate time point.
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F I G U R E 3 Mean (± SD) pre-and postplasmapheresis endogenous C1-INH functional activity (measured prior to study drug dosing). Shows depletion of endogenous C1-INH activity by plasmapheresis in a randomized, doubleblind, placebo-controlled pilot study of C1-INH (Cinryze) in acute AMR. From Montgomery RA et al 87 . AMR, antibodymediated rejection; C1-INH, C1 esterase inhibitor; SD, standard deviation As clinically apparent chronic renal allograft injury and long-term graft loss due to AMR is a relatively infrequent event among the general transplant population and may take several years to manifest, prospective randomized clinical trials required to assess the benefits of therapeutic intervention require large sample sizes that are hard to accrue, long time frames, and great expense. Although use of short-term allograft loss as a clinical endpoint would shorten the time frame, events would be even more infrequent, requiring an even larger sample size.
Given these challenges and current treatment needs, there is increasing interest in the use of predictive measures of short-term graft function and eventually surrogate endpoints (SEPs) and the possibility of using an accelerated approval pathway for AMR therapeutics. Renal function (eGFR), DSAs, and graft histology have been used as predictive endpoints in renal transplant trials for some time, and all have been shown to have some correlation with late transplant outcomes. 106 However, questions remain regarding the rigor that must be exercised in order for these predictive endpoints to become acceptable SEPs to the field of AMR and among regulatory bodies such as the FDA. Also, should they be measured at a given time point, or is change over time more appropriate? Most importantly, does the information gained from use of SEPs predict long-term outcomes? Use of composite primary endpoints is common in clinical trials in transplantation, so it holds that composite SEPs may be feasible in AMR as well and would overcome some of the limitations associated with use of individual SEPs.
| CONCLUSION
Much progress has been made in advancing our understanding of AMR as a disease process and in improving classification and risk stratification. However, there is much room for improvement in these areas before prevention and treatment strategies can be optimized. 
